Tratamentos estéticos e cuidados dos cabelos: uma visão médica (parte 1) / Hair care: a medical overview (part 1)

Dúvidas sobre a ação dos cosméticos capilares sobre a saúde do corpo e dos cabelos são cada vez mais frequentes nas consultas dermatológicas. Os médicos dermatologistas necessitam enriquecer o conhecimento a respeito, não somente, das doenças do couro cabeludo, como também das interações moleculares dos cosméticos usados na fibra capilar, incluindo a influência de tais produtos quando absorvidos pelo epitélio do couro cabeludo. A cada dia, aumentam as consultas médicas para esclarecimento de quais técnicas e produtos químicos são mais indicados para permitir que os cabelos sofram as alterações desejadas de seu aspecto natural e, ao mesmo tempo, mantenhamse saudáveis e belos. Neste artigo, dividido em duas partes, abordamos a fisiologia dos cabelos, sua estrutura e natureza química, os agentes usados para seu alisamento, sua coloração, higiene e seu tratamento estético e as consequências que tais procedimentos podem ter na saúde em geral, incluindo sua segurança no uso durante a gravidez e lactação.

Doubts concerning the action of hair cosmetics and the health of both body and hair are very frequent in the dermatological visits. Dermatologists need no only to enrich the knowledge of scalp diseases but also of molecular interactions of cosmetics used in hair fi ber, including the infl uence of such products when absorbed by the epithelium of the scalp. The amount of medical visits increases every day to fi nd out which techniques and chemical products are best indicated to enable the desired changes in hair from its natural appearance and, at the same time, to keep the hair healthy and beautiful. In this article, divided in two parts, we discuss the hair physiology, structure and chemical nature, as well as the agents used for its smoothing, coloring, hygiene and cosmetic treatment, and the consequences that such procedures can have on overall health, including their use safety during pregnancy and lactation.

The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia.

Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeutic program - negative Polymerase Chain Reaction (PCR) - developed a severe cutaneous vasculitis, receiving the diagnostic of type II mixed cryoglobulinemia. Four sessions of plasmapheresis were prescribed along the period of 11 days, with no result. The choice made was to administer anti-CD 20 monoclonal antibody (rituximab), 375 mg/m(2), per week, during four consecutive weeks. One could observe fast recovery from the purpura, as well as total remission of urticaria.

The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia

Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeutic program - negative Polymerase Chain Reaction (PCR) - developed a severe cutaneous vasculitis, receiving the diagnostic of type II mixed cryoglobulinemia. Four sessions of plasmapheresis were prescribed along the period of 11 days, with no result. The choice made was to administer anti-CD 20 monoclonal antibody (rituximab), 375 mg/m², per week, during four consecutive weeks. One could observe fast recovery from the purpura, as well as total remission of urticaria.